Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lotilaner SCHEMBL16860871 | 1.00 | CCR1 (0.33) | CCR1LMNAPTGES | |
| SCHEMBL2505425 | 0.94 | CCR1 (0.33) | CCR1LMNA | |
| SCHEMBL23874305 | 0.94 | CCR1 (0.33) | CCR1LMNA | |
| SCHEMBL2496669 | 0.92 | CCR1 (0.35) | CCR1LMNA | |
| SCHEMBL19272772 | 0.92 | CCR1 (0.34) | CCR1LMNA | |
| SCHEMBL25586455 | 0.91 | CCR1 (0.39) | CCR1 | |
| SCHEMBL2507781 | 0.91 | CCR1 (0.35) | CCR1LMNA | |
| SCHEMBL29224834 | 0.90 | CCR1 (0.33) | CCR1 | |
| SCHEMBL29224829 | 0.90 | CCR1 (0.33) | CCR1 | |
| SCHEMBL17734096 | 0.90 | CCR1 (0.33) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245239-A1 | ORGANIC COMPOUNDS | ELANCO TIERGESUNDHEIT AG (CH) | 2011-10-06 | — | — | US | claimed |
| WO-2026041786-A1 | INJECTABLE VETERINARY COMPOSITION AND USES THEREOF | INTERVET INTERNATIONAL B.V. (NL) | 2026-02-26 | — | — | WO | disclosed |
| US-20260021076-A1 | ISOXAZOLINE AND MACROCYCLIC LACTONE MICROSPHERES | ZOETIS SERVICES LLC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4580627-A1 | TREATMENT OF FASCIOLOSIS | Intervet International B.V. (NL) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024201231-A1 | A PROCESS FOR THE PREPARATION OF ISOXAZOLINE-SUBSTITUTED AMIDE COMPOUNDS AND ITS INTERMEDIATES THEREOF | HIKAL LIMITED (IN) | 2024-10-03 | — | — | WO | disclosed |
| EP-4358941-A1 | PALATABLE VETERINARY COMPOSITIONS | Intervet International B.V. (NL) | 2024-05-01 | — | — | EP | disclosed |
| EP-4351341-A1 | TICK CONTROL METHODS | Intervet International B.V. (NL) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024047241-A1 | TREATMENT OF FASCIOLOSIS | INTERVET INTERNATIONAL B.V. (NL) | 2024-03-07 | — | — | WO | disclosed |
| US-20230257370-A1 | PROCESS FOR MAKING AN ISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | SHANGHAI STA PHARMACEUTICAL R&D CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| WO-2023012821-A1 | A PROCESS FOR THE PREPARATION OF CARBAMOYL BENZAMIDE PHENYL ISOXAZOLINE CLASS DRUG/S AND ITS INTERMEDIATES | ZENFOLD SUSTAINABLE TECHNOLOGIES PRIVATE LIMITED (IN) | 2023-02-09 | — | — | WO | disclosed |
| US-20170208806-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170208805-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210723-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170208803-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170208804-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170020848-A1 | EXTENDED RELEASE INJECTABLE FORMULATIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEREOF | MERIAL INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-20160317502-A1 | USE OF ISOXAZOLINE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ARTHROPOD INFESTATIONS IN POULTRY | INTERVET INC. (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2016164487-A1 | EXTENDED RELEASE INJECTABLE FORMULATIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEREOF | MERIAL, INC. (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160256442-A1 | LONG-ACTING INJECTABLE FORMULATIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEROF | MERIAL, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| WO-2016138339-A1 | LONG-ACTING INJECTABLE FORMULATIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEREOF | MERIAL, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170208803-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | ACHE, DDT, MSMO1 | CCR1 4110/4885LMNA 3113/4885PTGES 157/4885 |
| US-20170210723-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | ACHE, DDT, MSMO1 | CCR1 4110/4885LMNA 3113/4885PTGES 157/4885 |
| US-20260021076-A1 | ISOXAZOLINE AND MACROCYCLIC LACTONE MICROSPHERES | MTX2, CYP3A7, MIF | CCR1 4155/4885LMNA 901/4885PTGES 2530/4885 |
| US-20230257370-A1 | PROCESS FOR MAKING AN ISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | CYP3A7, CYP4Z1, CYP2A7 | CCR1 4298/4885LMNA 1563/4885PTGES 4189/4885 |
| US-20160256442-A1 | LONG-ACTING INJECTABLE FORMULATIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEROF | MACF1, RTF1, PRDX5 | CCR1 1907/4885LMNA 1801/4885PTGES 552/4885 |
| US-20160317502-A1 | USE OF ISOXAZOLINE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ARTHROPOD INFESTATIONS IN POULTRY | CYP4X1, XDH, CYP2A7 | CCR1 4023/4885LMNA 2459/4885PTGES 2257/4885 |
| US-20170208806-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | ACHE, DDT, MSMO1 | CCR1 4110/4885LMNA 3113/4885PTGES 157/4885 |
| US-20110245239-A1 | ORGANIC COMPOUNDS | ACHE, VDAC1, VDAC2 | CCR1 4087/4885LMNA 3796/4885PTGES 1056/4885 |
| US-20170208804-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | ACHE, DDT, MSMO1 | CCR1 4110/4885LMNA 3113/4885PTGES 157/4885 |
| US-20170208805-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | ACHE, DDT, MSMO1 | CCR1 4110/4885LMNA 3113/4885PTGES 157/4885 |
| US-20170020848-A1 | EXTENDED RELEASE INJECTABLE FORMULATIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEREOF | IPO7, MMP1, CYP3A7 | CCR1 2660/4885LMNA 1610/4885PTGES 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.